Neuronetics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Neuronetics, Inc. (STIM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$9.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$15.17M, a 959.49% decline year-over-year.
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $1.76M.
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$11.95M.
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$14.90M.
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $14.68M.
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$40.22M.
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$10.66M.
- Neuronetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$23.80M, a 152.68% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$9.19M 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | -$15.17M 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | $14.68M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $15.01M 10-Q · filed 2025-11-04 | ||||
| 2025-06-30 | -$1.99M 10-Q · filed 2026-08-11 | ||||
| 2025-03-31 | $1.76M 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | -$40.22M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | -$38.81M 10-Q · filed 2025-11-04 | ||||
| 2024-06-30 | -$17.04M 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | -$11.95M 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | -$10.66M 10-K · filed 2026-03-17 | ||||
| 2023-09-30 | -$811.67K 8-K/A · filed 2025-02-06 | -$34.49M 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | -$24.43M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | -$14.90M 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | -$23.80M 10-K · filed 2025-03-27 | ||||
| 2022-09-30 | -$20.44M 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | -$23.21M 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | -$13.30M 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | $45.18M 10-K · filed 2024-03-08 | ||||
| 2021-09-30 | $50.48M 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $66.83M 10-Q · filed 2022-08-02 | ||||
| 2021-03-31 | $72.32M 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | -$26.75M 10-K · filed 2023-03-07 | ||||
| 2020-09-30 | -$24.99M 10-Q · filed 2021-11-09 | ||||
| 2020-06-30 | -$21.71M 10-Q · filed 2021-08-03 | ||||
| 2020-03-31 | -$12.06M 10-Q · filed 2021-05-04 | ||||
| 2019-12-31 | -$28.88M 10-K · filed 2022-03-08 | ||||
| 2019-09-30 | -$22.21M 10-Q · filed 2020-11-02 | ||||
| 2019-06-30 | -$14.94M 10-Q · filed 2020-08-04 | ||||
| 2019-03-31 | -$8.44M 10-Q · filed 2020-05-05 | ||||
| 2018-12-31 | $75.44M 10-K · filed 2021-03-02 | ||||
| 2018-09-30 | $77.61M 10-Q · filed 2019-11-05 | ||||
| 2018-06-30 | -$14.60M 10-Q · filed 2019-08-06 | ||||
| 2018-03-31 | -$8.79M 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $12.11M 10-K · filed 2020-03-03 | ||||
| 2017-09-30 | $7.11M 10-Q · filed 2018-11-06 | ||||
| 2016-12-31 | -$3.97M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |